



SciTech Development, LLC

SciTech Invited to NYC Oncology Investor Conference November 12-13, 2019

(GROSSE POINTE FARMS, MI) October 30, 2019 – [SciTech Development](#), a clinical stage drug development company, is pleased to announce that it has been invited to participate in the



NYC Oncology Investor Conference - 1155 6th Ave 22nd Floor, New York, NY. The conference will be held on November 12 and 13 and includes leading life science and oncology venture capitalists, family offices, lawyers, pharma executives, startup public and private cancer companies and cancer foundations for a discussion on trends, opportunities and risks in oncology investing. The conference will feature corporate presentations by a select group of public and private oncology companies, and updates on cutting edge science.

SciTech will be presenting its ST-001 [nanoFenretinide](#) technology, which is a small-molecule cancer drug employing a nanoparticle suspension for intravenous administration. ST-001 is comprised of [fenretinide](#) in a patented combination with carefully selected non-toxic phospholipids. SciTech's [product pipeline](#) includes fenretinide formulations for the treatment of several [cancer indications](#).

The company has submitted an Investigational New Drug (IND) Application for ST-001 nanoFenretinide and the FDA has granted it Orphan Drug Status for the treatment of two types of non-Hodgkin's lymphoma (NHL): peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

Information regarding SciTech's nano formulation technology and oncology drug product ST-001 nanoFenretinide is available from SciTech Development, LLC by calling +1-313-938-5517 or online at <https://www.scitechdevelopment.com/>.



About SciTech Development

SciTech Development, LLC is a clinical stage drug development company currently bringing to market a proven cancer drug for diseases with otherwise limited therapeutic options. SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | +1-313-263-4887 | eth@scitechdevelopment.com

About the New York Oncology Investor Conference

The New York Oncology Investor Conference 2019 will be held on November 12 and 13 at 1155 6th Ave 22nd Floor, New York, NY. The National Foundation for Cancer Research (NFCR) and Perkins Coie are the presenting sponsors. Other sponsors include Cooley law firm, MWE law firm, Venable law firm, Altru Institute, Torreya Partners and Marcum. More information regarding the conference can be found online at <https://www.oncologyinvestorconference.com/>.

For More Information About SciTech: Earle T. Holsapple, President
SciTech Development, LLC
(313) 938-5517

Forward-Looking Information

This press release and linked information contains forward-looking statements, including information about management's view of SciTech Development LLC ("the Company"), future expectations, plans and prospects. In particular, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this release and linked information other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release and linked information are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by SciTech Development LLC.



####